Edition:
United States

Pharming Group NV (PHGUF.PK)

PHGUF.PK on OTC Markets Group - US Other OTC and Grey Market

0.27USD
11 Jan 2017
Change (% chg)

-- (--)
Prev Close
$0.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,967
52-wk High
$0.34
52-wk Low
$0.17

PHGUF.PK

Chart for PHGUF.PK

About

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products... (more)
No analyst recommendations are available for PHGUF.PK.

Overall

No Ratios Available.

Financials

  PHGUF.PK Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -- -- --
ROI: -- -1.00 14.82
ROE: -- -0.71 16.24

BRIEF-EC amends marketing authorisation for Pharming Group's Ruconest to include self-administration

* European Commission amends marketing authorisation for Ruconest to include self-administration

Jan 16 2017

BRIEF-Pharming announces financing plans for closing of RUCONEST North American rights acquisition

* Launches rights issue to raise 12.1 million euros ($12.86 million) as part of Ruconest North American rights acquisition

Nov 22 2016

BRIEF-Pharming Group's Ruconest gets positive opinion to include self-administration from CHMP

* CHMP adopts positive opinion to include self-administration for Ruconest

Nov 11 2016

Fitch Affirms ATLANTICLUX's IFS at 'BBB+', Outlook Stable

(The following statement was released by the rating agency) FRANKFURT/LONDON, November 10 (Fitch) Fitch Ratings has affirmed Luxembourg-based ATLANTICLUX Lebensversicherung S.A.'s (ATL) Insurer Financial Strength (IFS) rating at 'BBB+' and Long-Term Issuer Default Rating (IDR) at 'BBB'. The Outlooks are Stable. Fitch has also affirmed ATL's SQ ReVita value of business in-force (VIF) transaction and Salam III Sukuk (Islamic bond) programme at 'BBB'. KEY RATING DRIVERS The affirmation reflects

Nov 10 2016

BRIEF-Pharming Group expects to become profitable at operating level in 2017

* Pharming reports on financial results for the first nine months of 2016

Oct 27 2016

BRIEF-Pharming Group 8-month product sales rise to 6.2 million euros

* 8-month product sales 6.2 million euros ($6.97 million)versus 5.6 million euros year ago

Oct 03 2016

Valeant looks to sell billions in assets to cut debt, stock soars

Valeant Pharmaceuticals International Inc will sell billions of dollars of non-core assets and could accept offers for its main businesses, its chief executive said on Tuesday, as the drugmaker worked to restore investor trust after a year of bad news.

Aug 09 2016

UPDATE 6-Valeant looks to sell billions in assets to cut debt, stock soars

Aug 9 Valeant Pharmaceuticals International Inc will sell billions of dollars of non-core assets and could accept offers for its main businesses, its chief executive said on Tuesday, as the drugmaker worked to restore investor trust after a year of bad news.

Aug 09 2016

BRIEF-Pharming Group announces acquisition of all North American commercialisation rights to Ruconest from Valeant

* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant

Aug 09 2016

BRIEF-Valeant Pharmaceuticals Q2 GAAP loss per share $0.88

Aug 9 Valeant Pharmaceuticals International Inc :

Aug 09 2016

Earnings vs. Estimates